Moderna (MRNA) Financial Analysis & Valuation | Quarter Chart
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its r... more
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therap... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $96.40B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Stéphane Bancel |
| IPO Date | 2018-12-07 | CAGR | 37.82% |
| Employees | 4,700 | Website | www.modernatx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
MRNA chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $101.89B | P/E | -29.63 | Forward P/E | -52.66 | PEG | — |
| P/S | 4527439640073721798112070074368 | P/B | 1489488859917569969558109814784 | P/CF | -9567670000916936057265376460800 | P/FCF | -8249898397564470622014530387968 |
| Sales | $2.23B | Sales 1Y | -27.19% | Sales 3Y | -78.88% | Sales 5Y | -66.68% |
| EPS | $-8.15 | EPS 1Y | 6.01% | EPS 3Y | -392.31% | EPS 5Y | -199.5% |
| Sales QoQ | -62.72% | EPS QoQ | -42.35% | Sales QoQ Avg | 119.22% | EPS QoQ Avg | 64.11% |
| Gross Margin | -12.57% | Operating Margin | -149.01% | Profit Margin | -141.43% | ROCE | -39.4% |
| ROA | -29% | ROE | -39% | Altman Z Score | 14.06 | Piotroski Score | 2 |
| Current Ratio | 2.29 | Quick Ratio | 2.18 | Cash Ratio | 0.68 | Op. CF Ratio | -0.21 |
| Debt/Equity | 0.18 | Debt/Assets | 0.11 | Lt Debt/Equity | 0.18 | Lt Debt/Cap. | 0.15 |
| Intrst Cov. | -415 | Inventory Turnover | 8.96 | Asset Turnover | 0.2 | Receivables Turnover | 131.06 |
| Enterprise Value | $101.89B | P/E Ratio | -29.63 |
| Forward P/E | -52.66 | PEG Ratio | — |
| P/S Ratio | 4527439640073721798112070074368 | P/B Ratio | 1489488859917569969558109814784 |
| P/CF Ratio | -9567670000916936057265376460800 | P/FCF Ratio | -8249898397564470622014530387968 |
| EPS | $-8.15 | EPS Growth 1Y | 6.01% |
| EPS Growth 3Y | -392.31% | EPS Growth 5Y | -199.5% |
| Revenue Growth 1Y | -27.19% | Gross Margin | -12.57% |
| Operating Margin | -149.01% | Profit Margin | -141.43% |
| ROE | -39% | ROA | -29% |
| ROCE | -39.4% | Current Ratio | 2.29 |
| Quick Ratio | 2.18 | Cash Ratio | 0.68 |
| Debt/Equity | 0.18 | Interest Coverage | -415 |
| Altman Z Score | 14.06 | Piotroski Score | 2 |
Moderna (MRNA) valuation & financials
Moderna (MRNA) has a market capitalization of $96.40B and trades at a price-to-earnings ratio of -29.6. It operates in the Healthcare sector (Biotechnology).
Moderna's revenue grew -27.2% over the last year.
Moderna's next earnings report is scheduled for November 6, 2026 before market open (provider scheduled date); analysts estimate EPS of $-1.09. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)